PL3013814T3 - Podstawione związki tetrahydrokarbazolu i karbazolu karboksamidu użyteczne jako inhibitory kinazy - Google Patents
Podstawione związki tetrahydrokarbazolu i karbazolu karboksamidu użyteczne jako inhibitory kinazyInfo
- Publication number
- PL3013814T3 PL3013814T3 PL14740094T PL14740094T PL3013814T3 PL 3013814 T3 PL3013814 T3 PL 3013814T3 PL 14740094 T PL14740094 T PL 14740094T PL 14740094 T PL14740094 T PL 14740094T PL 3013814 T3 PL3013814 T3 PL 3013814T3
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- compounds useful
- carboxamide compounds
- carbazole carboxamide
- substituted tetrahydrocarbazole
- Prior art date
Links
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 1
- GFHHIWFKWFBNRU-UHFFFAOYSA-N 9h-carbazole-1-carboxamide Chemical class C12=CC=CC=C2NC2=C1C=CC=C2C(=O)N GFHHIWFKWFBNRU-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 | |
| EP14740094.9A EP3013814B1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3013814T3 true PL3013814T3 (pl) | 2017-11-30 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14740094T PL3013814T3 (pl) | 2013-06-25 | 2014-06-25 | Podstawione związki tetrahydrokarbazolu i karbazolu karboksamidu użyteczne jako inhibitory kinazy |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (pl) |
| EP (1) | EP3013814B1 (pl) |
| JP (1) | JP6353529B2 (pl) |
| KR (1) | KR102346508B1 (pl) |
| CN (1) | CN105358546B (pl) |
| AR (1) | AR096721A1 (pl) |
| AU (1) | AU2014302548B2 (pl) |
| BR (1) | BR112015030723A8 (pl) |
| CA (1) | CA2916500A1 (pl) |
| CL (1) | CL2015003635A1 (pl) |
| CY (1) | CY1119371T1 (pl) |
| DK (1) | DK3013814T3 (pl) |
| EA (1) | EA026729B1 (pl) |
| ES (1) | ES2636652T3 (pl) |
| HR (1) | HRP20171031T1 (pl) |
| HU (1) | HUE034460T2 (pl) |
| IL (1) | IL243296B (pl) |
| LT (1) | LT3013814T (pl) |
| MA (1) | MA38648B1 (pl) |
| MY (1) | MY176631A (pl) |
| PE (1) | PE20160519A1 (pl) |
| PH (1) | PH12015502630A1 (pl) |
| PL (1) | PL3013814T3 (pl) |
| PT (1) | PT3013814T (pl) |
| RS (1) | RS56371B1 (pl) |
| SI (1) | SI3013814T1 (pl) |
| SM (1) | SMT201700422T1 (pl) |
| TN (1) | TN2015000529A1 (pl) |
| TW (1) | TWI648272B (pl) |
| UY (1) | UY35625A (pl) |
| WO (1) | WO2014210085A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105473573B (zh) | 2013-06-25 | 2018-03-16 | 百时美施贵宝公司 | 用作激酶抑制剂的咔唑甲酰胺化合物 |
| CA2965516A1 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
| PT3461821T (pt) | 2014-10-24 | 2020-08-05 | Bristol Myers Squibb Co | Compostos de indol carboxamida úteis como inibidores de quinase |
| TN2017000158A1 (en) * | 2014-10-24 | 2018-10-19 | Bristol Myers Squibb Co | Carbazole derivatives |
| MX2018015793A (es) | 2016-07-01 | 2019-03-21 | Brio Device Llc | Estilete de intubación con alimentación de video. |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| EP3558977B1 (en) | 2016-12-20 | 2020-10-28 | Bristol-Myers Squibb Company | Process for preparing tetrahydrocarbazole carboxamide compound |
| WO2019208805A1 (ja) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240216330A1 (en) | 2021-04-02 | 2024-07-04 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| AR128498A1 (es) * | 2022-02-15 | 2024-05-15 | Hoffmann La Roche | Procesos novedosos |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1812442A2 (en) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
| EA014956B1 (ru) | 2004-12-17 | 2011-04-29 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений |
| MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| JP2009508872A (ja) * | 2005-09-16 | 2009-03-05 | セレネックス， インコーポレイテッド | カルバゾール誘導体 |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8518964B2 (en) | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| EP2270200A3 (en) | 2006-09-11 | 2011-07-13 | CGI Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| US8263648B2 (en) | 2006-09-11 | 2012-09-11 | Mylan Laboratories Ltd. | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| CA2707491A1 (en) | 2007-12-13 | 2009-06-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| WO2009102498A1 (en) | 2008-02-14 | 2009-08-20 | Siemens Medical Solutions Usa, Inc. | Novel imaging agents for detecting neurological dysfunction |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| BRPI0922565A2 (pt) * | 2008-12-19 | 2015-12-15 | Bristol Myers Squibb Co | compostos de carbazol carboxamida úteis como inibidores de cinase |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| EP2552914B1 (de) | 2010-03-26 | 2015-11-11 | Merck Patent GmbH | Benzonaphthyridinamine als autotaxin-inhibitoren |
| EP2582668B1 (en) * | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| CA2817896A1 (en) | 2010-11-15 | 2012-05-24 | Viiv Healthcare Uk Limited | Inhibitors of hiv replication |
| CA2834077A1 (en) | 2011-05-17 | 2012-11-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en not_active Ceased
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
- 2014-06-25 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh not_active Expired - Fee Related
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko not_active Expired - Fee Related
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| IL256500A (en) | Heterocyclic amides as kinase inhibitors | |
| IL243296B (en) | Tetrahydrocarbazole and carbazole carboxamide compounds are useful as kinase inhibitors | |
| ZA201601697B (en) | Substituted pyrimidine bmi-1 inhibitors | |
| IL244224A0 (en) | Pyro- and Thiane-Pyrimide Carboxamide Compounds for Use as Pim Kinase Inhibitors | |
| IL243295A0 (en) | Carbazole carboxamide compounds are useful as kinase inhibitors | |
| IL240962A0 (en) | cdc7 inhibitors | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors | |
| HK1224673A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| GB201307155D0 (en) | Kinase inhibitors |